Health and Economic Outcomes of Introducing the New MenB Vaccine (Bexsero) into the Italian Routine Infant Immunisation Programme
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Health and Economic Outcomes of Introducing the New MenB Vaccine (Bexsero) into the Italian Routine Infant Immunisation Programme
Authors
Keywords
Vaccines, Vaccination and immunization, Italian people, Meningococcal disease, Booster doses, Cost-effectiveness analysis, Infants, Epidemiology
Journal
PLoS One
Volume 10, Issue 4, Pages e0123383
Publisher
Public Library of Science (PLoS)
Online
2015-04-14
DOI
10.1371/journal.pone.0123383
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty
- (2014) Sophie M Andrews et al. LANCET INFECTIOUS DISEASES
- Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study
- (2014) H. Christensen et al. BMJ-British Medical Journal
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement
- (2013) Don Husereau et al. BMC Medicine
- Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials
- (2013) Timo Vesikari et al. LANCET
- Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment
- (2013) Ulrich Vogel et al. LANCET INFECTIOUS DISEASES
- Bactericidal Antibody Persistence 2 Years After Immunization With 2 Investigational Serogroup B Meningococcal Vaccines at 6, 8 and 12 Months and Immunogenicity of Preschool Booster Doses
- (2013) Matthew D. Snape et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact
- (2013) Hannah Christensen et al. VACCINE
- Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage
- (2013) Giacomo Frosi et al. VACCINE
- Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB)
- (2013) Julie A. Bettinger et al. VACCINE
- Persistence of antibodies in adolescents 18−24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine
- (2013) Maria Elena Santolaya et al. Human Vaccines & Immunotherapeutics
- Cost-effectiveness of vaccination against meningococcal B among Dutch infants
- (2013) Koen B. Pouwels et al. Human Vaccines & Immunotherapeutics
- WHO/Health Canada meeting on regulatory considerations for evaluation and licensing of new meningococcal Group B vaccines, Ottawa, Canada, 3–4 October 2011
- (2012) Ian Feavers et al. BIOLOGICALS
- Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules
- (2012) Nicoletta Gossger et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study
- (2012) María Elena Santolaya et al. LANCET
- Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study
- (2012) Russell M Viner et al. LANCET NEUROLOGY
- The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: Immunological, functional and structural characterization of the antigens
- (2012) Davide Serruto et al. VACCINE
- Invasive meningococcal disease in England and Wales: Implications for the introduction of new vaccines
- (2012) Shamez N. Ladhani et al. VACCINE
- A Systematic Review and Meta-Analysis of Utility-Based Quality of Life in Chronic Kidney Disease Treatments
- (2012) Melanie Wyld et al. PLOS MEDICINE
- Arthritis, Occupational Class, and the Aging US Workforce
- (2011) Alberto J. Caban-Martinez et al. AMERICAN JOURNAL OF PUBLIC HEALTH
- Results from evaluations of models and cost-effectiveness tools to support introduction decisions for new vaccines need critical appraisal
- (2011) Raymond Hutubessy et al. BMC Medicine
- Comparative Long-term Adverse Effects Elicited by Invasive Group B and C Meningococcal Infections
- (2011) M. Gottfredsson et al. CLINICAL INFECTIOUS DISEASES
- National decision-making on adopting new vaccines: a systematic review
- (2011) H. E. D. Burchett et al. HEALTH POLICY AND PLANNING
- Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC)
- (2011) Faruque Ahmed et al. VACCINE
- The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology
- (2010) Vanessa N Racloz et al. BMC INFECTIOUS DISEASES
- Characterization of fHbp, nhba (gna2132), nadA, porA, and Sequence Type in Group B Meningococcal Case Isolates Collected in England and Wales during January 2008 and Potential Coverage of an Investigational Group B Meningococcal Vaccine
- (2010) J. Lucidarme et al. Clinical and Vaccine Immunology
- Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis
- (2010) Karen Edmond et al. LANCET INFECTIOUS DISEASES
- Serogroup B meningococcal vaccines—an unfinished story
- (2010) Manish Sadarangani et al. LANCET INFECTIOUS DISEASES
- Advances in the Development of Vaccines againstNeisseria meningitidis
- (2010) Lionel K.K. Tan et al. NEW ENGLAND JOURNAL OF MEDICINE
- EuroQol (EQ-5D) health utility scores for patients with migraine
- (2010) Ruifeng Xu et al. QUALITY OF LIFE RESEARCH
- Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus
- (2010) Marzia M. Giuliani et al. VACCINE
- Incidence of bacterial meningitis (2001–2005) in Lazio, Italy: the results of a integrated surveillance system
- (2009) Paolo Giorgi Rossi et al. BMC INFECTIOUS DISEASES
- Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs
- (2009) Caroline L Trotter et al. Expert Review of Vaccines
- Health status utilities and the impact of pressure ulcers in long-term care residents in Ontario
- (2009) Hla-Hla Thein et al. QUALITY OF LIFE RESEARCH
- Decision support in vaccination policies
- (2009) B. Piso et al. VACCINE
- Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000–2006
- (2009) Laura M. Kinlin et al. VACCINE
- Meningococcal carriage and disease—Population biology and evolution
- (2009) Dominique A. Caugant et al. VACCINE
- Global epidemiology of meningococcal disease
- (2009) Lee H. Harrison et al. VACCINE
- Economics of an Adolescent Meningococcal Conjugate Vaccination Catch-up Campaign in the United States
- (2008) Ismael R. Ortega Sanchez et al. CLINICAL INFECTIOUS DISEASES
- Cost-effectiveness of introducing the conjugated pneumococcal vaccine to routine free immunizations for infants in Lazio, Italy
- (2008) Paolo Giorgi-Rossi et al. HEALTH POLICY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now